a-L-岩藻糖苷酶联合甲胎蛋白检测在原发性肝癌诊断中的临床评价  

Clinical evaluation of combined AFU and AFP detection in diagnosis for patients with primary hepatic carcinoma

作　　者：黄鑫刚[1] 史小波[1] 郭新荣[1] 

机构地区：[1]南通大学第二附属医院检验科,江苏南通226001

出　　处：《检验医学与临床》2012年第7期779-780,共2页Laboratory Medicine and Clinic

摘　　要：目的评价a-L-岩藻糖苷酶(AFU)与甲胎蛋白(AFP)联合检测在原发性肝癌(PHC)诊断中的临床意义。方法 PHC 92例、良性肝病42例和健康对照组90例,采用连续监测法检测AFU,采用化学发光法检测AFP,并进行相关统计学分析。结果 PHC患者血清AFP、AFU的敏感性分别为67.39%和75.00%,明显高于良性肝病组和健康对照组(P<0.05)。联合检测AFP、AFU,其诊断的敏感性和准确性达到91.30%和91.04%,均比单项检测高。结论 AFU是诊断PHC良好的血清肿瘤标志物。AFP与AFU联合检测,可提高诊断PHC的敏感性和准确性,有助于PHC的诊断、病情变化判别及治疗效果观察。Objective To study the clinical significance of combined serum a L-fucosidase （AFU） and alpha- fetoprotein（AFP） detection for the diagnosis of primary hepatic carcinoma（PHC）. Methods Serum level of AFU and AFP was measured by continuous monitoring method and chemiluminescence in 92 patients with primary hepatic car- cinoma,42 patients with benign liver disease and 90 normal controls. Then, some statistical analysis for these data were done. Results The sensitiviy of serum AFP and AFU in primary hepatic carcinoma was 67. 390/00 and 75.00% respedively, significantly higher than that of benign liver disease and normal controls（P〈0.05）. The diagnostic sensitivity and accuracy of serum AFP and AFU combined detection was 91.30% and 91.04% respedively, higher than that of single assay. Conclusion AFU can be used as a good tumor marker of detection of PHC. Combined AFU and AFP detection will improve the sensitivity and accuracy of the diagnosis of PHC, contribute to diagnose primary hepatic carcinoma ,judge the disease condition and investigate the curative effect.

关 键 词：A-L-岩藻糖苷酶 甲胎蛋白 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]